May 15, 2015
Researchers from Johns Hopkins University have developed a PET radiopharmaceutical for imaging metastatic prostate cancer that so far has shown superior image quality with less radiation exposure in most radiosensitive organs than its predecessor.
The first human study of the agent, F-18 DCFPyL, was published online April 21 in Molecular Imaging and Biology. The researchers found that the small-molecule prostate-specific membrane antigen (PSMA) inhibitor caused no serious adverse events.
DCFPyL showed so much promise in preclinical studies that word about it is starting to spread, according to its developer and senior study author Dr. Martin Pomper, PhD.
"Now I have people all over the country who are trying to come here to get scanned with this agent," he said.